Eliem Therapeutics (NASDAQ:ELYM) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.38) by 23.68 percent. This is a 27.5 percent increase over losses of $(0.40) per share from the same period last year.
‘This Is A Beautiful, Bullish Chart’: Analysts Remain Upbeat As Bitcoin Dips Below $40K
While Bitcoin (CRYPTO: BTC) prices spiral downwards to below $40,000, some technical analyst suggest this drop is temporary before an upw
